市場調查報告書

抗癌劑的全球市場的分析與預測:各疾病,主力醫藥品 2019年∼2026年

Cancer Therapeutics Market by Application and Top Selling Drugs : Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 648137
出版日期 內容資訊 英文 261 Pages
商品交期: 2-3個工作天內
價格
Back to Top
抗癌劑的全球市場的分析與預測:各疾病,主力醫藥品 2019年∼2026年 Cancer Therapeutics Market by Application and Top Selling Drugs : Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2019年07月05日內容資訊: 英文 261 Pages
簡介

全球抗癌劑市場在2018年估算為989億美元,在2019年∼2026年間預測將以7.7%的年複合成長率發展,到2026年成長到1,801億9,300萬美元的規模。

本報告提供全球抗癌劑治療調查,市場概要,各疾病、主力醫藥品、地區的市場規模的變化與預測,市場佔有率,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 報告概要
  • 相關利益者的優點
  • 主要市場區隔
    • 調查對象企業
  • 調查方法
    • 2次調查
    • 1次調查
    • 分析師的工具和模式

第2章 摘要整理

  • 調查結果

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 市場佔有率分析
  • 波特的五力分析
  • 臨床試驗
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會

第4章 全球抗癌劑市場:各疾病

  • 概要
  • 血液癌症
    • 主要的市場趨勢、成長要素、市場機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 肺癌症
  • 乳癌
  • 大腸癌症
  • 前列腺癌症
  • 子宮頸癌症
  • 頭頸椎癌症
  • 神經膠質母細胞瘤
  • 惡性腦膜瘤
  • 中皮腫
  • 黑色素瘤
  • 其他

第5章 全球抗癌劑市場:各主力醫藥品

  • 概要
  • Revlimid
    • 市場規模的變化與預測:各地區
    • 市場分析:各地區
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec/Glivec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Temodar
  • 其他

第6章 全球抗癌劑市場:各地區

  • 概要
  • 北美
    • 主要的市場趨勢、成長要素、市場機會
    • 市場規模的變化與預測:各國、各疾病
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲

第7章 企業簡介

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI_18480

The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.

Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.

However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.

The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
  • Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
  • An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

  • By Application
  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Cervical Cancer
  • Head and Neck Cancer
  • Glioblastoma
  • Malignant Meningioma
  • Mesothelioma
  • Melanoma
  • Others
  • By Top Selling Drugs
  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Temodar
  • Others
  • By Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Taiwan
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle-East
  • Africa

The list of key players operating in this market include:

  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company
  • AbbVie, Inc.
  • Johnson & Johnson
  • Celgene Corporation
  • Astellas Pharma, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Merck KGaA
  • Eli Lilly and Company

The other players included in the value chain analysis (and not included in the report) include:

  • AstraZeneca plc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. KEY FINDINGS OF THE STUDY
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. Market share analysis, 2018
  • 3.4. Porters five forces analysis
  • 3.5. Clinical trials
  • 3.6. Market dynamics
    • 3.6.1. Drivers
      • 3.6.1.1. Increase in prevalence of cancer
      • 3.6.1.2. Surge in cancer research
      • 3.6.1.3. Rise in strategic acquisitions & collaborations
    • 3.6.2. Restraints
      • 3.6.2.1. High cost of drug development and threat of failure
      • 3.6.2.2. Adverse effects associated with cancer drug therapy
    • 3.6.3. Opportunities
      • 3.6.3.1. High potential associated with personalized medicines
      • 3.6.3.2. Increase in purchasing power of emerging economies

CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Blood cancer
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market analysis, by country
  • 4.3. Lung cancer
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market analysis, by country
  • 4.4. Breast cancer
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market analysis, by country
  • 4.5. Colorectal cancer
    • 4.5.1. Key market trends, growth factors, and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market analysis, by country
  • 4.6. Prostate cancer
    • 4.6.1. Key market trends, growth factors, and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market analysis, by country
  • 4.7. Cervical cancer
    • 4.7.1. Key market trends, growth factors, and opportunities
    • 4.7.2. Market size and forecast, by region
    • 4.7.3. Market analysis, by country
  • 4.8. Head & neck cancer
    • 4.8.1. Key market trends, growth factors, and opportunities
    • 4.8.2. Market size and forecast, by region
    • 4.8.3. Market analysis, by country
  • 4.9. Glioblastoma
    • 4.9.1. Key market trends, growth factors, and opportunities
    • 4.9.2. Market size and forecast, by region
    • 4.9.3. Market analysis, by country
  • 4.10. Malignant meningioma
    • 4.10.1. Key market trends, growth factors, and opportunities
    • 4.10.2. Market size and forecast, by region
    • 4.10.3. Market analysis, by country
  • 4.11. Mesothelioma
    • 4.11.1. Key market trends, growth factors, and opportunities
    • 4.11.2. Market size and forecast, by region
    • 4.11.3. Market analysis, by country
  • 4.12. Melanoma
    • 4.12.1. Key market trends, growth factors, and opportunities
    • 4.12.2. Market size and forecast, by region
    • 4.12.3. Market analysis, by country
  • 4.13. Others
    • 4.13.1. Key market trends, growth factors, and opportunities
    • 4.13.2. Market size and forecast, by region
    • 4.13.3. Market analysis, by country

CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Revlimid
    • 5.2.1. Market size and forecast, by region
    • 5.2.2. Market analysis, by region
  • 5.3. Avastin
    • 5.3.1. Market size and forecast, by region
    • 5.3.2. Market analysis, by region
  • 5.4. Herceptin
    • 5.4.1. Market size and forecast, by region
    • 5.4.2. Market analysis, by region
  • 5.5. Rituxan
    • 5.5.1. Market size and forecast, by region
    • 5.5.2. Market analysis, by region
  • 5.6. Opdivo
    • 5.6.1. Market size and forecast, by region
    • 5.6.2. Market analysis, by region
  • 5.7. Gleevec
    • 5.7.1. Market size and forecast, by region
    • 5.7.2. Market analysis, by region
  • 5.8. Velcade
    • 5.8.1. Market size and forecast, by region
    • 5.8.2. Market analysis, by region
  • 5.9. Imbruvica
    • 5.9.1. Market size and forecast, by region
    • 5.9.2. Market analysis, by region
  • 5.10. Ibrance
    • 5.10.1. Market size and forecast, by region
    • 5.10.2. Market analysis, by region
  • 5.11. Zytiga
    • 5.11.1. Market size and forecast, by region
    • 5.11.2. Market analysis, by region
  • 5.12. Alimta
    • 5.12.1. Market size and forecast, by region
    • 5.12.2. Market analysis, by region
  • 5.13. Xtandi
    • 5.13.1. Market size and forecast, by region
    • 5.13.2. Market analysis, by region
  • 5.14. Tarceva
    • 5.14.1. Market size and forecast, by region
    • 5.14.2. Market analysis, by region
  • 5.15. Perjeta
    • 5.15.1. Market size and forecast, by region
    • 5.15.2. Market analysis, by region
  • 5.16. Temodar
    • 5.16.1. Market size and forecast, by region
    • 5.16.2. Market analysis, by region
  • 5.17. Other drugs
    • 5.17.1. Market size and forecast, by region
    • 5.17.2. Market analysis, by region

CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors, and opportunities
    • 6.2.2. North America market size and forecast, by country
      • 6.2.2.1. U.S.
      • 6.2.2.1.1. U.S. market size and forecast, by application
      • 6.2.2.2. Canada
      • 6.2.2.2.1. Canada market size and forecast, by application
    • 6.2.3. North America market size and forecast, by application
    • 6.2.4. North America market size and forecast, by top selling drugs
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors, and opportunities
    • 6.3.2. Europe cancer therapeutics market, by country
      • 6.3.2.1. Germany
      • 6.3.2.1.1. Germany market size and forecast, by application
      • 6.3.2.2. France
      • 6.3.2.2.1. France market size and forecast, by application
      • 6.3.2.3. UK
      • 6.3.2.3.1. UK market size and forecast, by application
      • 6.3.2.4. Italy
      • 6.3.2.4.1. Italy market size and forecast, by application
      • 6.3.2.5. Spain
      • 6.3.2.5.1. Spain market size and forecast, by application
      • 6.3.2.6. Rest of Europe
      • 6.3.2.6.1. Rest of Europe market size and forecast, by application
    • 6.3.3. Europe market size and forecast, by application
    • 6.3.4. Europe market size and forecast, by top selling drugs
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors, and opportunities
    • 6.4.2. Asia-Pacific market size and forecast, by country
      • 6.4.2.1. Japan
      • 6.4.2.1.1. Japan market size and forecast, by application
      • 6.4.2.2. China
      • 6.4.2.2.1. China market size and forecast, by application
      • 6.4.2.3. India
      • 6.4.2.3.1. India market size and forecast, by application
      • 6.4.2.4. Taiwan
      • 6.4.2.4.1. Taiwan market size and forecast, by application
      • 6.4.2.5. South Korea
      • 6.4.2.5.1. South Korea market size and forecast, by application
      • 6.4.2.6. Australia
      • 6.4.2.6.1. Australia market size and forecast, by application
      • 6.4.2.7. Rest of Asia-Pacific
      • 6.4.2.7.1. Rest of Asia-Pacific market size and forecast, by application
    • 6.4.3. Asia-Pacific market size and forecast, by application
    • 6.4.4. Asia-Pacific market size and forecast, by top selling drugs
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors, and opportunities
    • 6.5.2. LAMEA market size and forecast, by country
      • 6.5.2.1. Latin America
      • 6.5.2.1.1. Latin America market size and forecast, by application
      • 6.5.2.2. Middle East
      • 6.5.2.2.1. Middle East market size and forecast, by application
      • 6.5.2.3. Africa
      • 6.5.2.3.1. Africa market size and forecast, by application
    • 6.5.3. LAMEA market size and forecast, by application
    • 6.5.4. LAMEA market size and forecast, by top selling drugs

CHAPTER 7: COMPANY PROFILES

  • 7.1. AbbVie Inc.
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product portfolio
    • 7.1.5. Business performance
    • 7.1.6. Key strategic moves and developments
  • 7.2. Astellas Pharma Inc.
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product portfolio
    • 7.2.5. Business performance
    • 7.2.6. Key strategic moves and developments
  • 7.3. Bristol Myers Squibb Company
    • 7.3.1. Company overview
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Product portfolio
    • 7.3.5. Business performance
    • 7.3.6. Key strategic moves and developments
  • 7.4. Celgene Corporation
    • 7.4.1. Company overview
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segments
    • 7.4.4. Product portfolio
    • 7.4.5. Business performance
    • 7.4.6. Key strategic moves and developments
  • 7.5. Eli Lilly and Company
    • 7.5.1. Company overview
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Product portfolio
    • 7.5.5. Business performance
    • 7.5.6. Key strategic moves and developments
  • 7.6. F. Hoffmann-La Roche Ltd.
    • 7.6.1. Company overview
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Product portfolio
    • 7.6.5. EleInformatiBusiness performance
    • 7.6.6. Key strategic moves and developments
  • 7.7. Johnson & Johnson
    • 7.7.1. Company overview
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segments
    • 7.7.4. Product portfolio
    • 7.7.5. Business performance
    • 7.7.6. Key strategic moves and developments
  • 7.8. Merck & Co., Inc.
    • 7.8.1. Company overview
    • 7.8.2. Company snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Product portfolio
    • 7.8.5. Business performance
    • 7.8.6. Key strategic moves and developments
  • 7.9. Novartis AG
    • 7.9.1. Company overview
    • 7.9.2. Company snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Product portfolio
    • 7.9.5. Business performance
    • 7.9.6. Key strategic moves and developments
  • 7.10. Pfizer Inc.
    • 7.10.1. Company overview
    • 7.10.2. Company snapshot
    • 7.10.3. Operating business segments
    • 7.10.4. Product portfolio
    • 7.10.5. Business performance
    • 7.10.6. Key strategic moves and developments

List of Tables

  • TABLE 01. COMPLETED CLINICAL TRIALS IN CANCER THERAPEUTICS MARKET
  • TABLE 02. GLOBAL CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 03. BLOOD CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 04. LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 05. BREAST CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 06. COLORECTAL CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 07. PROSTATE CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 08. CERVICAL CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 09. HEAD & NECK CANCER THERAPEUTICS MARKET, BY REGION, 2019-2026 ($MILLION)
  • TABLE 10. GLIOBLASTOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019-2026 ($MILLION)
  • TABLE 11. MALIGNANT MENINGIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019-2026 ($MILLION)
  • TABLE 12. MESOTHELIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019-2026 ($MILLION)
  • TABLE 13. MELANOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019-2026 ($MILLION)
  • TABLE 14. OTHER CANCER THERAPEUTICS MARKET, BY REGION, 2019-2026 ($MILLION)
  • TABLE 15. GLOBAL CANCER THERAPEUTICS MARKET REVENUE, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
  • TABLE 16. REVLIMID CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 17. AVASTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 18. HERCEPTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 19. RITUXAN CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 20. OPDIVO CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 21. GLEEVEC CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 22. VELCADE CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 23. IMBRUVICA CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 24. IBRANCE CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 25. ZYTIGA CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 26. ALIMTA CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 27. XTANDI CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 28. TARCEVA CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 29. PERJETA CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 30. TEMODAR CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 31. CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 32. CANCER THERAPEUTICS MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 33. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 34. U.S. CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 35. CANADA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 36. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 37. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
  • TABLE 38. EUROPE CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 39. GERMANY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 40. FRANCE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 41. UK CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 42. ITALY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 43. SPAIN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 44. REST OF EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 45. EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 46. EUROPE CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
  • TABLE 47. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 48. JAPAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 49. CHINA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 50. INDIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 51. TAIWAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 52. SOUTH KOREA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 53. AUSTRALIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 54. REST OF ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 55. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 56. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
  • TABLE 57. LAMEA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
  • TABLE 58. LATIN AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 59. MIDDLE EAST CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 60. AFRICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 61. LAMEA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 62. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
  • TABLE 63. ABBVIE: COMPANY SNAPSHOT
  • TABLE 64. ABBVIE: OPERATING SEGMENTS
  • TABLE 65. ABBVIE: PRODUCT PORTFOLIO
  • TABLE 66. ASTELLAS: COMPANY SNAPSHOT
  • TABLE 67. ASTELLAS: PRODUCT PORTFOLIO
  • TABLE 68. BMS: COMPANY SNAPSHOT
  • TABLE 69. BMS: OPERATING SEGMENTS
  • TABLE 70. BMS: PRODUCT PORTFOLIO
  • TABLE 71. CELGENE: COMPANY SNAPSHOT
  • TABLE 72. CELGENE: OPERATING SEGMENTS
  • TABLE 73. CELGENE: PRODUCT PORTFOLIO
  • TABLE 74. ELI LILLY: COMPANY SNAPSHOT
  • TABLE 75. ELI LILLY: OPERATING SEGMENTS
  • TABLE 76. ROCHE: COMPANY SNAPSHOT
  • TABLE 77. ROCHE: OPERATING SEGMENTS
  • TABLE 78. ROCHE: PRODUCT PORTFOLIO
  • TABLE 79. J&J: COMPANY SNAPSHOT
  • TABLE 80. J&J: OPERATING SEGMENTS
  • TABLE 81. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 82. MERCK: COMPANY SNAPSHOT
  • TABLE 83. MERCK: OPERATING SEGMENTS
  • TABLE 84. MERCK: PRODUCT TYPE PORTFOLIO
  • TABLE 85. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 86. NOVARTIS: OPERATING SEGMENTS
  • TABLE 87. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 88. NOVARTIS: NET SALES, 2016-2018 ($MILLION)
  • TABLE 89. PFIZER: COMPANY SNAPSHOT
  • TABLE 90. PFIZER: OPERATING SEGMENTS
  • TABLE 91. PFIZER: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. GLOBAL CANCER THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 02. TOP INVESTMENT POCKETS
  • FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016-2018*
  • FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2018*
  • FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016-2018*
  • FIGURE 06. MARKET SHARE ANALYSIS, 2016
  • FIGURE 07. LOW BARGAINING POWER OF BUYERS
  • FIGURE 08. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 09. LOW THREAT OF NEW ENTRANTS
  • FIGURE 10. MODERATE THREAT OF SUBSTITUTION
  • FIGURE 11. HIGH COMPETITIVE RIVALRY
  • FIGURE 12. CANCER THERAPEUTICS MARKET: IMPACT ANALYSIS
  • FIGURE 13. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (MEN)
  • FIGURE 14. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (WOMEN)
  • FIGURE 15. COMPARATIVE COUNTRY ANALYSIS OF BLOOD CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 16. COMPARATIVE COUNTRY ANALYSIS OF LUNG CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 17. COMPARATIVE COUNTRY ANALYSIS OF BREAST CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 18. COMPARATIVE COUNTRY ANALYSIS OF COLORECTAL CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 19. COMPARATIVE COUNTRY ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 20. COMPARATIVE COUNTRY ANALYSIS OF CERVICAL CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 21. COMPARATIVE COUNTRY ANALYSIS OF HEAD & NECK CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 22. COMPARATIVE COUNTRY ANALYSIS OF GLIOBLASTOMA CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 23. COMPARATIVE COUNTRY ANALYSIS OF MALIGNANT MENINGIOMA CANCER THERAPEUTICS MARKET , 2018 & 2026 ($MILLION)
  • FIGURE 24. COMPARATIVE COUNTRY ANALYSIS OF MESOTHELIOMA CANCER THERAPEUTICS, 2018 & 2026 ($MILLION)
  • FIGURE 25. COMPARATIVE COUNTRY ANALYSIS OF MELANOMA CANCER THERAPEUTICS MARKET , 2018 & 2026 ($MILLION)
  • FIGURE 26. COMPARATIVE COUNTRY ANALYSIS OF OTHER CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
  • FIGURE 27. COMPARATIVE REGION ANALYSIS OF REVLIMID CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 28. COMPARATIVE REGION ANALYSIS OF AVASTIN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 29. COMPARATIVE REGION ANALYSIS OF HERCEPTIN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 30. COMPARATIVE REGION ANALYSIS OF RITUXAN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 31. COMPARATIVE REGION ANALYSIS OF OPDIVO CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 32. COMPARATIVE REGION ANALYSIS OF GLEEVEC CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 33. COMPARATIVE REGION ANALYSIS OF VELCADE CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 34. COMPARATIVE REGION ANALYSIS OF IMBRUVICA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 35. COMPARATIVE REGION ANALYSIS OF IBRANCE CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 36. COMPARATIVE REGION ANALYSIS OF ZYTIGA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 37. COMPARATIVE REGION ANALYSIS OF ALIMTA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 38. COMPARATIVE REGION ANALYSIS OF XTANDI CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 39. COMPARATIVE REGION ANALYSIS OF TARCEVA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 40. COMPARATIVE REGION ANALYSIS OF PERJETA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
  • FIGURE 41. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR TEMODAR, 2018 AND 2026 ($MILLION)
  • FIGURE 42. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, 2018 AND 2026 ($MILLION)
  • FIGURE 43. ABBVIE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 44. ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 45. ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 46. ASTELLAS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 47. ASTELLAS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 48. ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 49. BMS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 50. BMS: REVENUE SHARE BY SEGMENT, 2018(%)
  • FIGURE 51. BMS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 52. CELGENE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 53. CELGENE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 54. CELGENE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 55. ELI LILLY: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 56. ELI LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 57. ELI LILLY: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 58. ROCHE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 59. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 60. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 61. J&J: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 62. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 63. J&J: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 64. MERCK: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 65. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 66. MERCK: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 67. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 68. NOVARTIS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 69. PFIZER NET SALES, 2016-2018 ($MILLION)
  • FIGURE 70. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 71. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
Back to Top